FORA Capital LLC decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 71.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,729 shares of the medical research company's stock after selling 19,191 shares during the quarter. FORA Capital LLC's holdings in IQVIA were worth $1,832,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of IQV. Canada Pension Plan Investment Board boosted its holdings in IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company's stock valued at $719,634,000 after acquiring an additional 211,653 shares during the last quarter. Farallon Capital Management LLC boosted its stake in shares of IQVIA by 3.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company's stock valued at $618,046,000 after purchasing an additional 86,870 shares during the last quarter. FMR LLC grew its position in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after buying an additional 804,963 shares during the period. Impax Asset Management Group plc raised its stake in shares of IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company's stock worth $423,885,000 after buying an additional 157,809 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in IQVIA by 0.8% in the second quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company's stock valued at $320,170,000 after buying an additional 11,715 shares during the period. 89.62% of the stock is currently owned by institutional investors.
IQVIA Stock Up 0.1 %
Shares of IQVIA stock traded up $0.20 during trading on Thursday, reaching $201.43. The stock had a trading volume of 822,837 shares, compared to its average volume of 1,177,509. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market capitalization of $36.56 billion, a price-to-earnings ratio of 26.44, a P/E/G ratio of 2.10 and a beta of 1.51. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The stock has a fifty day moving average price of $220.36 and a two-hundred day moving average price of $226.57.
Analyst Upgrades and Downgrades
IQV has been the subject of several recent research reports. Morgan Stanley dropped their target price on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. Redburn Atlantic began coverage on IQVIA in a report on Monday, October 14th. They issued a "buy" rating and a $276.00 price objective for the company. Leerink Partners restated an "outperform" rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Truist Financial cut their price target on shares of IQVIA from $286.00 to $265.00 and set a "buy" rating on the stock in a research report on Monday, November 4th. Finally, Robert W. Baird decreased their price objective on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating for the company in a report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus target price of $256.50.
Read Our Latest Stock Report on IQV
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
